Source:http://linkedlifedata.com/resource/pubmed/id/15764170
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11-12
|
pubmed:dateCreated |
2005-3-16
|
pubmed:abstractText |
Growth hormone (GH)-secretion in HIV-lipodystrophy is impaired; however, GH-sensitivity of GH-target tissues remains to be evaluated. We measured overnight fasting concentrations of GH-sensitive insulin-like growth-factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) including GH binding protein (GHBP), a marker of GH-receptor sensitivity, in antiretroviral treated HIV-infected patients with (LIPO) and without lipodystrophy (NONLIPO) and antiretroviral naive HIV-infected patients (NAIVE). Three h GH-suppression tests using oral glucose were undertaken to determine dynamics of GH-secretion. IGF-I and IGFBP-3 were increased in LIPO compared with NONLIPO (p <0.05), but did not differ significantly between NONLIPO and NAIVE. Area under the curve of GH (AUC-GH) during the GH-suppression test was decreased in LIPO compared with NONLIPO (p <0.05). Ratio of limb to trunk fat, which was decreased in LIPO compared to NONLIPO and NAIVE (p <0.001), correlated positively with AUC-GH and rebound-GH (p <0.05). All groups displayed suppression of GH during the suppression test (p <0.05) and all groups, except LIPO, displayed a rebound of GH (p <0.05), which probably is explained by persistently increased plasma glucose in LIPO compared with NONLIPO and NAIVE (p <0.01). GHBP was inversely correlated with AUC-GH (p <0.01). Our data suggest that GH-target tissues in LIPO are at least as GH-sensitive as in HIV-infected patients without lipodystrophy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Human Growth Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor Binding...,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0036-5548
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
36
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
832-9
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15764170-Absorptiometry, Photon,
pubmed-meshheading:15764170-Adult,
pubmed-meshheading:15764170-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:15764170-Body Composition,
pubmed-meshheading:15764170-Glucose,
pubmed-meshheading:15764170-HIV Infections,
pubmed-meshheading:15764170-HIV-Associated Lipodystrophy Syndrome,
pubmed-meshheading:15764170-Human Growth Hormone,
pubmed-meshheading:15764170-Humans,
pubmed-meshheading:15764170-Insulin-Like Growth Factor Binding Protein 3,
pubmed-meshheading:15764170-Insulin-Like Growth Factor I,
pubmed-meshheading:15764170-Male,
pubmed-meshheading:15764170-Questionnaires
|
pubmed:year |
2004
|
pubmed:articleTitle |
Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy.
|
pubmed:affiliation |
Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark. oandersen@dadlnet.dk
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|